Luke Laffin, M.D.

New Capabilities

Leading the CTX310 clinical program at Cleveland Clinic

A single infusion of a CRISPR gene-editing therapy kept LDL cholesterol about 52% lower and triglycerides about 48% lower for a full year. The results, from a 15-patient trial, are the longest durability data yet for in vivo CRISPR in heart disease. They were presented at the European Society of Cardiology meeting and published in the New England Journal of Medicine.

Updated 1 hour ago